Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)13.02
  • Today's Change-0.14 / -1.06%
  • Shares traded2.80k
  • 1 Year change-25.17%
  • Beta0.9814
Data delayed at least 15 minutes, as of Nov 22 2024 08:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy4
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The 8 analysts offering 12 month price targets for Medios AG have a median target of 33.40, with a high estimate of 40.00 and a low estimate of 18.00. The median estimate represents a 153.80% increase from the last price of 13.16.
High204.0%40.00
Med153.8%33.40
Low36.8%18.00

Earnings history & estimates in EUR

On Aug 13, 2024, earnings of 0.10 per share.
The next earnings announcement is expected on Mar 31, 2025.
Average growth rate-5.48%
Medios AG reported annual 2023 earnings of 0.79 per share on Mar 27, 2024.
Average growth rate+16.63%
More ▼

Revenue history & estimates in EUR

Medios AG had 3rd quarter 2024 revenues of 493.20m. This missed the 542.40m estimate of the one analyst following the company. This was 14.37% above the prior year's 3rd quarter results.
Average growth rate+4.41%
Medios AG had revenues for the full year 2023 of 1.78bn. This was 10.80% above the prior year's results.
Average growth rate+41.84%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.